Welcome to our dedicated page for Sotera Health Co SEC filings (Ticker: SHC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Locating cobalt supply risks or litigation reserves buried deep inside Sotera Health鈥檚 disclosures can feel like searching for microbes in a cleanroom. Each SHC 10-K, 10-Q and 8-K weaves together sterilisation capacity data, radiation-sourced inventory details and complex environmental footnotes that easily top 200 pages. If you are asking, 鈥淲here can I find the Sotera Health quarterly earnings report 10-Q filing?鈥� or 鈥淗ow do I track Sotera Health insider trading Form 4 transactions?鈥�, you have arrived at the right place.
Stock Titan鈥檚 AI reads every sentence the moment it hits EDGAR and serves you instant, plain-English answers. Our platform converts dense accounting notes into concise takeaways, turning understanding Sotera Health SEC documents with AI from a chore into a two-minute read. Need a quick look at Sotera Health annual report 10-K simplified, a red-flag summary of an 8-K material recall, or Sotera Health Form 4 insider transactions real-time? It鈥檚 all here, refreshed continuously.
- Monitor Sotera Health executive stock transactions Form 4 minutes after they鈥檙e filed
- Review Sotera Health proxy statement executive compensation without scrolling through appendices
- Dive into Sotera Health earnings report filing analysis to compare segment margins quarter over quarter
- See Sotera Health 8-K material events explained with AI-generated context on capacity expansions or regulatory actions
Whether you鈥檙e modelling gamma irradiation demand or simply want Sotera Health SEC filings explained simply, our real-time dashboard delivers the insights professionals use to make informed decisions鈥攏o highlighter pens required.
Sotera Health reported consolidated net revenues of $294.3 million for the three months ended June 30, 2025, up from $276.6 million a year earlier, driven by higher service revenue in Sterigenics and steady contributions from Nordion and Nelson Labs. Gross profit rose to $166.6 million versus $152.8 million, and cash and cash equivalents increased to $332.4 million from $277.2 million at year-end, supporting liquidity.
The company recorded $34.0 million of Illinois EO litigation settlements during the quarter and established a $64.9 million reserve reflected in accrued liabilities and operating cash flows. Net income for the quarter was $8.0 million (basic EPS $0.03), while the six-month period produced a net loss of $5.3 million compared with net income of $15.1 million in the prior year period. Total assets were $3.217 billion, total liabilities $2.705 billion, and total equity improved to $511.3 million.
Sotera Health Company furnished a press release reporting its financial results for the quarter ended June 30, 2025 and scheduled a conference call at 9:00 a.m. Eastern Time to discuss those results. The press release is attached to the Form 8-K as Exhibit 99.1 and is incorporated by reference into the report.
The filing clarifies that the press release and related information are being furnished, not filed, and therefore are not subject to Section 18 liability. This Form 8-K does not include any financial figures or performance metrics; readers should consult the attached Exhibit 99.1 for the detailed results and disclosures.
FAQ
What is the current stock price of Sotera Health Co (SHC)?
What is the market cap of Sotera Health Co (SHC)?
